IPOS-1 filed
Scribe Therapeutics, Co-Founded by Nobel Laureate Jennifer Doudna, Files S-1 for Nasdaq IPO
Scribe Therapeutics filed its S-1 with the SEC on July 2, seeking to list on the Nasdaq Global Market under the ticker 'SCTX.' The clinical-stage biotech, co-founded by CRISPR pioneer and Nobel laureate Dr. Jennifer Doudna, has raised roughly $150 million in equity financing since 2017 and is advancing STX-1150 -- an epigenetic-silencing CRISPR candidate for cardiovascular disease -- through an Australian first-in-human trial, while disclosing only $49.7 million in cash and marketable securities against a $175.1 million accumulated deficit.
Jul 2, 2026